Last reviewed · How we verify
Risperidone low dose
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Risperidone low dose |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The low-dose formulation provides therapeutic benefit with potentially reduced extrapyramidal side effects compared to higher doses.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Irritability associated with autism spectrum disorder
- Aggression and behavioral disturbances in dementia
Common side effects
- Weight gain
- Sedation
- Akathisia
- Prolactin elevation
- Extrapyramidal symptoms
- Orthostatic hypotension
- Metabolic syndrome
Key clinical trials
- Subjective Experience Following Psilocybin (PHASE2)
- Study of a Novel Antipsychotic ITI-007 in Schizophrenia (PHASE2)
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
- Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety? (PHASE3)
- Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders (PHASE4)
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |